<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819272</url>
  </required_header>
  <id_info>
    <org_study_id>LCRM105</org_study_id>
    <nct_id>NCT01819272</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks</brief_title>
  <official_title>A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elcelyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elcelyx Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the effect of delayed-release metformin (Met DR) to placebo and extended
      release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body
      weight, and assessed the safety and tolerability of a range of doses of Met DR when
      administered in subjects with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks after the first dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks</measure>
    <time_frame>Baseline and 4 to 12 weeks after the first dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (%) at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks after the first dose of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>600 mg DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg delayed-release metformin once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg delayed-release metformin once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg delayed-release metformin once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg extended-release metformin once daily in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2000 mg XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 mg extended-release metformin once daily in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Met DR</intervention_name>
    <description>metformin delayed-release tablets</description>
    <arm_group_label>600 mg DR</arm_group_label>
    <arm_group_label>800 mg DR</arm_group_label>
    <arm_group_label>1000 mg DR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Met XR</intervention_name>
    <description>metformin extended-release tablets</description>
    <arm_group_label>1000 mg XR</arm_group_label>
    <arm_group_label>2000 mg XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo delayed-release tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female with T2DM who was ≥18 and ≤65 years of age at Visit 1

          2. Had a body mass index (BMI) of 25.0 kg/m² to 45.0 kg/m², inclusive, at Visit 1

          3. Screening HbA1c 7.0 to 9.5% (inclusive) at Visit 1 if treated with diet and exercise
             alone, or 6.0 to 9.5% (inclusive) if on a stable dose of either metformin or DPP-4
             inhibitor monotherapy for a minimum of 2 months at Visit 1, or a combination of these
             2 agents only on a stable regimen for a minimum of 2 months at Visit 1

          4. Had serum creatinine concentration of &lt;1.5 mg/dL (male) or &lt;1.4 mg/dL (female) and an
             estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m² based on the
             Modification of Diet in Renal Disease (MDRD) equation

          5. Had a fasting glucose concentration of &lt;280 mg/dL at Visit 1

          6. Had a stable body weight, i.e., not varying by &gt;5% for at least 6 months prior to
             Visit 1 as documented by the investigator

          7. Was male, or if female and met all of the following criteria:

               1. Not breastfeeding

               2. Negative pregnancy test result (human chorionic gonadotropin, beta subunit
                  [βhCG]) at Visit 1 (not applicable to hysterectomized females)

               3. If of child bearing potential (including perimenopausal women who have had a
                  menstrual period within 1 year), must have practiced and be willing to continue
                  to practice appropriate birth control during the entire duration of the study

          8. Had a physical examination and ECG with no clinically significant abnormalities as
             judged by the investigator at Visit 1

          9. Had no clinically significant laboratory test values (clinical chemistry, hematology,
             urinalysis) other than those expected in subjects with diabetes as judged by the
             investigator at Visit 1

         10. Either was not treated with or had been on a stable treatment regimen with any of the
             following medications for a minimum of 2 months prior to Visit 1:

               1. Hormone replacement therapy (female subjects)

               2. Oral contraceptives (female subjects)

               3. Antihypertensive agents

               4. Lipid-lowering agents

               5. Thyroid replacement therapy

               6. Antidepressant agents

               7. Testosterone therapy (male subjects)

         11. If on chronic thyroid pharmacologic therapy, had a serum thyroid-stimulating hormone
             test result within the normal range at Visit 1

         12. Was willing and able to follow study procedures

         13. Was able to read, understand, and sign the Informed Consent Form and an Authorization
             to Use and Disclose Protected Health Information form, answer the study questions,
             communicate with the investigator, and understand and comply with protocol
             requirements

        Exclusion Criteria:

          1. Had a clinically significant medical condition that could potentially affect study
             participation and/or personal well-being, as judged by the investigator, including but
             not limited to the following conditions:

               1. Hepatic disease

               2. Renal disease

               3. Gastrointestinal disease

               4. Endocrine disorder except T2DM

               5. Cardiovascular disease

               6. Central nervous system diseases

               7. Psychiatric or neurological disorders

               8. Organ transplantation

               9. Chronic or acute infection (e.g., tuberculosis, human immunodeficiency virus,
                  hepatitis B virus, or hepatitis C virus)

              10. Orthostatic hypotension, fainting spells or blackouts

              11. Allergy or hypersensitivity

          2. Clinically significant malignant disease (with the exception of basal and squamous
             cell carcinoma of the skin) within 5 years of Visit 1

          3. Had known hypersensitivity, intolerability, or allergies to metformin HCl or any
             component of study treatment

          4. Had a physical, psychological, or historical finding that, in the investigator's
             opinion, would make the subject unsuitable for the study

          5. Current drugs or alcohol abuse or had a history of abuse that in the investigator's
             opinion would cause the individual to be noncompliant with study procedures

          6. Had major surgery or a blood transfusion within 2 months of Visit 1 or was planning to
             donate blood during the study, or had a significant blood loss within 2 months prior
             to Visit 1

          7. Had been treated, was being treated, or was expected to require or undergo treatment
             with any of the following excluded medications:

               1. Insulin or sulphonylurea treatment within 3 months of Visit 1

               2. GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of
                  Visit 1

               3. Nifedipine within 3 months of Visit 1

               4. Systemic corticosteroids by oral, intravenous, intra-articular, or intra-muscular
                  route within 30 days of screening or for more than 1 week within 3 months of
                  Visit 1

               5. Prescription weight loss medications within 3 months of Visit 1

               6. Chronic or frequent use, in the judgment of the investigator, of any drug
                  treatment that affects gastric pH (prescription or over-the-counter), including
                  proton pump inhibitors or any antacids or medications such as Rolaids or Pepcid
                  within 1 month of Visit 1

               7. Had received or planned to receive any iodinated contrast dye within 1 week prior
                  to Visit 1 (Screening)

          8. Had a surgical gastrointestinal procedure that may impact the gut hormonal response to
             study medication

          9. History or presence of inflammatory bowel disease or other severe gastrointestinal
             disease, particularly those which may impact gastric emptying, such as gastroparesis,
             pyloric stenosis, gastric bypass surgery or gastric banding surgery

         10. Had received any investigational drug within 30 days (or five half-lives of the
             investigational drug, whichever was greater) of Visit 1

         11. Was an immediate family member (spouse, parent, child, or sibling; biological or
             legally adopted) of personnel directly affiliated with the study at the clinical study
             site, or was directly affiliated with the study at the clinical study site

         12. Was employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract
             worker, or designee responsible for the conduct of the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Lewin</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Institute - Wilshire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rubin Saavedra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance Against Diabetes / AAD Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydie Hazan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Axis Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Lipetz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Encompass Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audrey Lacour</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juno Research, LLC - Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Hurley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research South, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eli M Roth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sterling Research Group, Ltd. - Auburn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Strzinek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Protenium Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Marple</last_name>
    <role>Principal Investigator</role>
    <affiliation>Castlerock Clinical Research Consultants, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farah Sultan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Achieve Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Moretto</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Health Network - Indianapolis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azazuddin A Ahmed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apex Medical Research - Illinois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Strout</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coastal Carolina Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Pullman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Big Sky Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Collins</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charlotte Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hassman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Zemel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creekside Endocrine Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSRA Partners in Health, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Rosenstock</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dallas Diabetes and Endocrine Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Searcy Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Ong</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Huffman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meridien Research - Tampa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Vargas</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Orleans Center for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Almena Free</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pinnacle Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Short</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Raleigh, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Wilson</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Winston-Salem, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander White</last_name>
    <role>Principal Investigator</role>
    <affiliation>Progressive Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Brazg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Davis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Clinical Research, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Fogarty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spartanburg Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph DeFronzo</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig S Thompson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Craig S Thompson MD LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subodh Bhuchar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pioneer Research Solutions Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Greco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacksonville Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold Bays</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisville Metabolic and Atherosclerosis Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Lubin</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research - Norfolk, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Christiansen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diablo Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Lawless</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn J Lucas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes and Endocrinology Consultants, P.C.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Toro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juno Research, LLC - Katy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva M Heurich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chander Arora</last_name>
    <role>Principal Investigator</role>
    <affiliation>RAS Health Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Buchanan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Willamette Valley Clinical Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Blevins</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes &amp; Endocrinology, P.A. - Austin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Muir Physician Network Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Hoekstra</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research - Richmond, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lyle Myers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kentucky Diabetes Endocrinology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Shaw</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes and Endocrinology, P.A. - Round Rock</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Purvi Mehra</last_name>
    <role>Principal Investigator</role>
    <affiliation>eStudySite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Traci Turner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic and Atherosclerosis Research Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. Epub 2015 Aug 18.</citation>
    <PMID>26285584</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>August 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2015</results_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>600 mg DR</title>
          <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="P3">
          <title>800 mg DR</title>
          <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="P4">
          <title>1000 mg DR</title>
          <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="P5">
          <title>1000 mg XR</title>
          <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
        <group group_id="P6">
          <title>2000 mg XR</title>
          <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Glucose Control</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>600 mg DR</title>
          <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="B3">
          <title>800 mg DR</title>
          <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="B4">
          <title>1000 mg DR</title>
          <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="B5">
          <title>1000 mg XR</title>
          <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
        <group group_id="B6">
          <title>2000 mg XR</title>
          <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="10.22"/>
                    <measurement group_id="B2" value="53.5" spread="8.34"/>
                    <measurement group_id="B3" value="52.6" spread="9.69"/>
                    <measurement group_id="B4" value="51.8" spread="9.05"/>
                    <measurement group_id="B5" value="51.0" spread="9.62"/>
                    <measurement group_id="B6" value="52.0" spread="9.53"/>
                    <measurement group_id="B7" value="52.0" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="5.28"/>
                    <measurement group_id="B2" value="33.1" spread="5.74"/>
                    <measurement group_id="B3" value="33.5" spread="5.86"/>
                    <measurement group_id="B4" value="33.3" spread="5.55"/>
                    <measurement group_id="B5" value="32.8" spread="5.27"/>
                    <measurement group_id="B6" value="33.7" spread="5.22"/>
                    <measurement group_id="B7" value="33.3" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous T2DM Regimen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diet and exercise alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DPP-4 inhibitor alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin/DPP-4 inhibitor combination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.5" spread="36.70"/>
                    <measurement group_id="B2" value="147.5" spread="42.56"/>
                    <measurement group_id="B3" value="142.4" spread="34.60"/>
                    <measurement group_id="B4" value="141.4" spread="29.79"/>
                    <measurement group_id="B5" value="139.0" spread="34.22"/>
                    <measurement group_id="B6" value="148.9" spread="41.36"/>
                    <measurement group_id="B7" value="144.3" spread="36.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.19" spread="0.838"/>
                    <measurement group_id="B2" value="7.27" spread="0.864"/>
                    <measurement group_id="B3" value="7.17" spread="0.829"/>
                    <measurement group_id="B4" value="7.13" spread="0.899"/>
                    <measurement group_id="B5" value="7.10" spread="0.819"/>
                    <measurement group_id="B6" value="7.17" spread="0.869"/>
                    <measurement group_id="B7" value="7.17" spread="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176.5" spread="54.70"/>
                    <measurement group_id="B2" value="180.1" spread="49.72"/>
                    <measurement group_id="B3" value="162.9" spread="40.10"/>
                    <measurement group_id="B4" value="172.3" spread="44.45"/>
                    <measurement group_id="B5" value="165.7" spread="50.01"/>
                    <measurement group_id="B6" value="180.3" spread="57.52"/>
                    <measurement group_id="B7" value="173.0" spread="49.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.40" spread="0.951"/>
                    <measurement group_id="B2" value="7.45" spread="0.887"/>
                    <measurement group_id="B3" value="7.33" spread="0.908"/>
                    <measurement group_id="B4" value="7.37" spread="0.890"/>
                    <measurement group_id="B5" value="7.36" spread="0.997"/>
                    <measurement group_id="B6" value="7.38" spread="0.980"/>
                    <measurement group_id="B7" value="7.38" spread="0.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks</title>
        <time_frame>Baseline and 4 weeks after the first dose of study medication</time_frame>
        <population>Week 4 Evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>600 mg DR</title>
            <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O3">
            <title>800 mg DR</title>
            <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O4">
            <title>1000 mg DR</title>
            <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O5">
            <title>1000 mg XR</title>
            <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
          <group group_id="O6">
            <title>2000 mg XR</title>
            <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks</title>
          <population>Week 4 Evaluable</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-69" upper_limit="48"/>
                    <measurement group_id="O2" value="-11" lower_limit="-124" upper_limit="150"/>
                    <measurement group_id="O3" value="-13" lower_limit="-62" upper_limit="145"/>
                    <measurement group_id="O4" value="-18" lower_limit="-90" upper_limit="113"/>
                    <measurement group_id="O5" value="-12" lower_limit="-111" upper_limit="58"/>
                    <measurement group_id="O6" value="-25" lower_limit="-110" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0670</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-14.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.0</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1095</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-12.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.0</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-12.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.0</ci_lower_limit>
            <ci_upper_limit>-3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-28.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.0</ci_lower_limit>
            <ci_upper_limit>-17.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks</title>
        <time_frame>Baseline and 4 to 12 weeks after the first dose of study medication</time_frame>
        <population>Week 12 Evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>600 mg DR</title>
            <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O3">
            <title>800 mg DR</title>
            <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O4">
            <title>1000 mg DR</title>
            <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O5">
            <title>1000 mg XR</title>
            <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
          <group group_id="O6">
            <title>2000 mg XR</title>
            <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
        </group_list>
        <measure>
          <title>AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks</title>
          <population>Week 12 Evaluable</population>
          <units>mg/dL*week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="-784.0" upper_limit="698.0"/>
                    <measurement group_id="O2" value="-96.00" lower_limit="-894.0" upper_limit="414.0"/>
                    <measurement group_id="O3" value="-108.00" lower_limit="-556.0" upper_limit="612.0"/>
                    <measurement group_id="O4" value="-156.00" lower_limit="-782.0" upper_limit="522.0"/>
                    <measurement group_id="O5" value="-98.00" lower_limit="-880.0" upper_limit="314.0"/>
                    <measurement group_id="O6" value="-215.00" lower_limit="-856.0" upper_limit="186.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0226</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-106.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-208.0</ci_lower_limit>
            <ci_upper_limit>-16.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0068</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-106.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-180.0</ci_lower_limit>
            <ci_upper_limit>-32.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-152.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-252.0</ci_lower_limit>
            <ci_upper_limit>-42.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0405</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-101.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-208.0</ci_lower_limit>
            <ci_upper_limit>-4.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>p-value for pair-wise comparison without adjustment</p_value_desc>
            <method>Kruskal-Wallis</method>
            <param_type>Hodges-Lehmann Estimation</param_type>
            <param_value>-224.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-334.0</ci_lower_limit>
            <ci_upper_limit>-118.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c (%) at 12 Weeks</title>
        <time_frame>Baseline and 12 weeks after the first dose of study medication</time_frame>
        <population>Week 12 Evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>600 mg DR</title>
            <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O3">
            <title>800 mg DR</title>
            <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O4">
            <title>1000 mg DR</title>
            <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
          </group>
          <group group_id="O5">
            <title>1000 mg XR</title>
            <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
          <group group_id="O6">
            <title>2000 mg XR</title>
            <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (%) at 12 Weeks</title>
          <population>Week 12 Evaluable</population>
          <units>HbA1c (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.137"/>
                    <measurement group_id="O2" value="-0.03" spread="0.125"/>
                    <measurement group_id="O3" value="0.00" spread="0.121"/>
                    <measurement group_id="O4" value="0.10" spread="0.124"/>
                    <measurement group_id="O5" value="0.00" spread="0.132"/>
                    <measurement group_id="O6" value="-0.21" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>ANCOVA</method>
            <method_desc>Factor for treatment and baseline HbA1c as a covariate</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <method>ANCOVA</method>
            <method_desc>Factor for treatment and baseline HbA1c as a covariate</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0611</p_value>
            <method>ANCOVA</method>
            <method_desc>Factor for treatment and baseline HbA1c as a covariate</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0188</p_value>
            <method>ANCOVA</method>
            <method_desc>Factor for treatment and baseline HbA1c as acovariate</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>Factor for treatment and baseline HbA1c as a covariate</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 83 to 107 days depending on the number of intervening days between study visits</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>600 mg DR</title>
          <description>600 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="E3">
          <title>800 mg DR</title>
          <description>800 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="E4">
          <title>1000 mg DR</title>
          <description>1000 mg delayed-release metformin once daily in the morning
Met DR: metformin delayed-release tablets</description>
        </group>
        <group group_id="E5">
          <title>1000 mg XR</title>
          <description>1000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
        <group group_id="E6">
          <title>2000 mg XR</title>
          <description>2000 mg extended-release metformin once daily in the evening
Met XR: metformin extended-release tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intravascular haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR’s request, delay submission while the SPONSOR files applications for patents.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Development</name_or_title>
      <organization>Elcelyx Therapeutics, Inc</organization>
      <phone>858-876-1814</phone>
      <email>info@elcelyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

